- Home
- CHRS vs SIFY Comparison
CHRS vs SIFY Comparison
Compare CHRS & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SIFY
- Stock Information
- Founded
- CHRS 2010
- SIFY 1995
- Country
- CHRS United States
- SIFY India
- Employees
- CHRS N/A
- SIFY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SIFY Computer Software: Programming Data Processing
- Sector
- CHRS Health Care
- SIFY Technology
- Exchange
- CHRS Nasdaq
- SIFY Nasdaq
- Market Cap
- CHRS 156.0M
- SIFY 244.1M
- IPO Year
- CHRS 2014
- SIFY 1999
- Fundamental
- Price
- CHRS $0.85
- SIFY $3.73
- Analyst Decision
- CHRS Buy
- SIFY
- Analyst Count
- CHRS 6
- SIFY 0
- Target Price
- CHRS $7.10
- SIFY N/A
- AVG Volume (30 Days)
- CHRS 3.0M
- SIFY 213.7K
- Earning Date
- CHRS 11-04-2024
- SIFY 10-22-2024
- Dividend Yield
- CHRS N/A
- SIFY N/A
- EPS Growth
- CHRS N/A
- SIFY N/A
- EPS
- CHRS N/A
- SIFY N/A
- Revenue
- CHRS $308,134,000.00
- SIFY $437,955,969.00
- Revenue This Year
- CHRS $5.18
- SIFY N/A
- Revenue Next Year
- CHRS $16.86
- SIFY $14.01
- P/E Ratio
- CHRS N/A
- SIFY N/A
- Revenue Growth
- CHRS 69.37
- SIFY 6.71
- 52 Week Low
- CHRS $0.85
- SIFY $1.80
- 52 Week High
- CHRS $3.73
- SIFY $12.30
- Technical
- Relative Strength Index (RSI)
- CHRS 28.71
- SIFY 66.56
- Support Level
- CHRS $0.98
- SIFY $3.21
- Resistance Level
- CHRS $1.01
- SIFY $4.14
- Average True Range (ATR)
- CHRS 0.08
- SIFY 0.39
- MACD
- CHRS -0.01
- SIFY 0.14
- Stochastic Oscillator
- CHRS 0.00
- SIFY 80.48
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SIFY Sify Technologies Limited
Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.